HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Growth hormone therapy.

Abstract
Growth hormone from human pituitary glands has been available for 30 years. Because of the scarce supply and the danger of transmitting Creutzfeldt-Jakob disease, use of the hormone was discontinued in 1984. Fortunately, synthetic growth hormone produced with recombinant DNA technology became available in 1985 and eliminated the risk of Creutzfeldt-Jakob disease. Growth hormone is approved for use in the treatment of pituitary deficiency syndromes and, when properly administered at an early stage, is capable of inducing normal skeletal and muscular development. It also has been successfully used to augment growth in patients with Turner's syndrome or constitutional growth delay not associated with obvious growth hormone defects. Side effects are generally not serious, but antibodies to growth hormone develop in about 30 percent of patients.
AuthorsL Shulman, J L Miller, L I Rose
JournalAmerican family physician (Am Fam Physician) Vol. 41 Issue 5 Pg. 1541-6 (May 1990) ISSN: 0002-838X [Print] United States
PMID2333830 (Publication Type: Journal Article)
Chemical References
  • Growth Hormone
Topics
  • Growth Disorders (drug therapy)
  • Growth Hormone (adverse effects, deficiency, therapeutic use)
  • Humans
  • Turner Syndrome (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: